Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 4 1Phase 1/2 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Psoriasis 4Lymphoma, Follicular 4Uveitis 1Pruritus 1Pneumonia 1Plaque, Amyloid 1Cachexia 1Bronchiolitis Obliterans Syndrome 1Arthritis, Rheumatoid 1Arthritis, Juvenile 1Anorexia 1

Interventions

tofacitinib 7Etanercept 4Adalimumab 2secukinumab 1apremilast 1Methotrexate 1Anti-Infective Agents, Local 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Psoriasis × Etanercept × Clear all
NCT01241591 2018-12-26

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Pfizer

Phase 3 Completed
1,101 enrolled 46 charts
Lymphoid

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Pruritus, Psoriasis, Plaque, Amyloid

NCT01313221 2017-03-15

REFINE

Amgen

Phase 3 Completed
310 enrolled 32 charts
Lymphoid

Lymphoma, Follicular, Psoriasis

NCT00111449 2013-05-15

Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis

Amgen

Phase 3 Completed
600 enrolled
Lymphoid

Lymphoma, Follicular, Psoriasis

NCT00111436 2013-04-26

Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects

Amgen

Phase 3 Completed
912 enrolled
Lymphoid

Lymphoma, Follicular, Psoriasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡